RT Journal Article SR Electronic T1 EPINEPHRINE AND CHOLESTEROL METABOLISM IN THE DOG. HEPATIC METABOLISM OF PYRUVATE AND MEVALONATE IN VITRO JF Journal of Pharmacology and Experimental Therapeutics JO J Pharmacol Exp Ther FD American Society for Pharmacology and Experimental Therapeutics SP 151 OP 157 VO 151 IS 1 A1 Joseph H. Gans YR 1966 UL http://jpet.aspetjournals.org/content/151/1/151.abstract AB The administration of epinephrine in oil, 1 mg free base/kg/day for 7 days to adult male dogs, resulted in significant increases in plasma and liver cholesterol concentrations. The in vitro incorporation of C14 from pyruvate-3-C14 into cholesterol, total lipid and CO2 and from mevalonate-2-C14 into cholesterol and CO2 by liver slices from epinephrine-treated dogs was not different from the metabolism of these substrates by liver slices from control dogs. Liver slices from dogs fed cholesterol for 9 to 11 days showed significant decreases in the incorporation of C14 from pyruvate-3-C14 into cholesterol. Significant increases in plasma cholesterol concentrations were observed in cholesterol-fed dogs treated with epinephrine in oil, but C14 incorporation from pyruvate-3-C14 into cholesterol was almost completely inhibited in liver slices from these dogs. Decreases in C14 incorporation from pyruvate-3-C14 into cholesterol were demonstrated in liver slices taken from cholesterol-fed dogs treated with epinephrine for 2 days. Increased plasma cholesterol concentrations in epinephrinetreated dogs, therefore, did not result from increased hepatic cholesterol synthesis. Epinephrine-induced hypercholesterolemia probably resulted from an influx of extrahepatic sterol into the liver plasma cholesterol pool. The Williams & Wilkins Comapny